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ABSTRACT
In both research and therapeutic applications
of RNA interference, it is often advantageous to
silence several targets simultaneously. Toward this
end, several groups have developed vectors that
utilize the model of endogenously encoded micro
(mi) RNAs, where a single RNA polymerase II
promoter can drive the expression of multiple
interfering RNAs. Stronger pol III promoters have
been used to drive individual short hairpin (sh)
RNAs, but to date, it has been necessary to repeat
the promoter in each silencing cassette to achieve
multiplexed expression from a single vector. Here,
we show that it is possible to drive polycistronic
expression from a single pol III promoter when
the interfering RNAs are formatted to resemble
miRNAs rather than shRNAs. As many as four
miRNAs designed to target hepatitis B virus (HBV)
transcripts are shown to be processed and func-
tional in reporter assays as well as in the context
of replicating virus in cell culture systems.
Although it has been observed that high levels of
expression of shRNAs can lead to cytotoxicity, we
find no significant evidence in transient transfection
assays that the HBV-miRNAs produced by our
vectors compete for the activity of endogenously
produced miR-122 or for processing of an exogen-
ously expressed miR-EGFP.
INTRODUCTION
The development of technologies that use RNA interfer-
ence (RNAi) to control gene expression has had a large
impact in numerous areas of research and has provided
opportunities for new therapeutic strategies in the treat-
ment of genetic and infectious diseases. For many
applications, it is proving advantageous to utilize multiple
interfering RNAs that can simultaneously target diﬀerent
gene products. This is particularly true in the development
of RNAi-based antiviral therapeutics, where the use
of several interfering RNAs can help to induce strong
suppression of viral replication across a broad range of
naturally occurring genotypic variants as well as to sup-
press the emergence of escape mutants [reviewed in (1)].
A number of diﬀerent methods have been used to
generate multiple interfering RNAs to suppress viral
replication. A mixture of several short interfering (si)
RNAs, produced exogenously by chemical synthesis or
by endonuclease III treatment of longer double-stranded
RNAs, has been eﬀective against hepatitis C and B virus
(HCV and HBV) and can help reduce viral escape in cell
culture and animal models of infection (2–4). Multiple
siRNAs can also be produced by intracellular dicing of
long hairpin (lh) RNAs with stem structures as long as
50–100bp. By introducing base changes into the sense
strand of these intracellularly transcribed lhRNAs, to
partially disrupt their double-stranded structure, it was
possible to retain silencing activity against HCV (5) or
HBV RNAs (6) without inducing an interferon response.
It has also been demonstrated that multiple anti-HIV
siRNAs that target noncontiguous sites can be processed
from a pol III driven lhRNA, although silencing activity
derived predominantly from the siRNA encoded closest to
the base of the hairpin (7).
Additional approaches for multiplexed silencing have
utilized plasmid or viral vectors capable of expressing mul-
tiple interfering RNAs that are formatted as short hairpin
(sh) or micro (mi) RNAs. Often, pol III promoters are
used to express shRNAs, sometimes together with other
RNA-based eﬀectors such as decoys or antisense RNAs,
that silence viral transcripts or cellular RNAs necessary
for viral replication. This strategy has shown good success
against viruses including HIV-1, HCV and HBV that
otherwise would readily escape the eﬃcacy of single
shRNAs (8–12). In all cases, however, a separate promoter
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multiplexed vector and this can be problematic. For
instance, the repetition of H1 promoters in an anti-HIV
lentiviral vector led to a high rate of recombination and
deletion of the shRNA expression cassettes, diminishing
the vector’s antiviral eﬃcacy and resistance to escape (13).
To avoid this problem, it was necessary to use a diﬀerent
pol III promoter to drive the expression of each shRNA
(13). Alternatively, multiple interfering RNAs that are
designed to resemble endogenous miRNAs can be
processed from a single RNA pol II transcript. The eﬃ-
cacy of pol II driven polycistronic antiviral miRNAs has
been demonstrated for HIV-1 and HBV (14–17).
The use of either pol II or pol III promoters to drive
expression of silencing cassettes each brings both
advantages and disadvantages, and diﬀerent modes of
expression will be appropriate in diﬀerent applications.
In general, pol II promoters can be utilized for cell type
speciﬁc expression or regulation and for eﬃcient expres-
sion of more than one interfering RNAs from a single
transcript. On the other hand, pol III promoters are ubi-
quitously expressed and stronger, potentially leading to
more potent silencing from low copy number vectors.
While it has been shown both theoretically (18) and
experimentally (12,13) that viral escape is reduced by
strong, multiplexed silencing, it is also true that high
expression levels of shRNAs can be toxic in cell systems
and in animals (19–21). Evidence is emerging, however,
that miRNAs are better tolerated and less likely to
induce toxic eﬀects (21–24). In the work described here,
we have explored whether a single pol III promoter can
be used to drive the expression of multiple miRNA-
formatted interfering RNAs, thereby combining the
advantages of multiplexed silencing from a compact and
nonrepetitive expression cassette with the strength of a
pol III promoter and the lower toxicity of the miRNA
conﬁguration.
MATERIALS AND METHODS
Plasmid constructions
We have previously described the construction of plasmids
that encode RNA pol II-driven multiplexed miRNAs
designed to target diﬀerent regions of HBV transcripts
(15). In the experiments described here, the Xba I/Spe I
fragment of pLV-30s/1737B/1907A, which encodes 1737B
and 1907A HBV-miRNAs, was PCR ampliﬁed using a
forward primer (50-CTAGGTCGACCACTATTATTTC
TATCGTCTAGAAGGC-30) that adds a Sal I site and
retains the Xba I site at the 50-end of the amplicon, and
a reverse primer (50-GGTACCAAAAAACGGCTGCTG
AATCGACTAGTAGCC-30) that retains the Spe I site
and adds a (T)6 termination signal followed by a Kpn I
site at the 30-end. (Restriction sites are underlined in the
primer sequences.) This Sal I/Kpn I fragment was inserted
immediately downstream of a pol III promoter in a pUC-
19-based plasmid where the promoter is ﬂanked by 50-Pst I
and 30-Sal I restriction sites. The 2791B HBV-miRNA
Xba I/Spe I fragment was removed from a monocistronic
plasmid and inserted into either the Xba I site or the Spe I
site to generate tricistronic plasmids. The 2910A HBV-
miRNA fragment was assembled from oligonucleotides
as previously described (15) and inserted into the Xba I
site or the Spe I site of a tricistronic plasmid to generate
polycistronic plasmids encoding four HBV miRNAs in
the order 1737B/1907A/2791B/2910A or 2910A/2791B/
1737B/1907A (Figure 1). The 2910A target sequence is
TCGTGGTGGACTTCTCTCAATT near position 2910
in the HBV (strain ayw) genome (GenBank accession
number V01460.1), and other target sequences are
reported in (15). The human U6 promoter was ampliﬁed
from pUC-U6-30/EGFP using a forward primer
(50-AAACTGCAGGATCCCCCCGAGTCCA-30) to add
a Pst I site at the 50-end and a reverse primer (50-CCTA
GTCGACTGGTATATGTGCTGCC-30) to add a Sal I
site and destroy the Spe I site at the 30-end of the
promoter. All constructions were conﬁrmed by DNA
sequencing.
The HBV infectious molecular clone, pHBV/2 and
psiCHECK-2 dual luciferase reporter vectors containing
HBV target sequence have been described (15). The
reporter plasmids psiCH-CAT360 and psiCH-CAT1454
contain, respectively, 360 and 1454bp of sequence encod-
ing the 30-UTR of human cationic amino acid transporter
(CAT-1) mRNA inserted into the Renilla luciferase
30-UTR in psiCHECK-2. These regions correspond to
those included in luciferase reporter plasmids RL-catC
(for CAT360) and RL-catB (for CAT1454) constructed
and characterized by Bhattacharyya et al. (25). The
CAT360 sequence contains no predicted targets for miR-
122 and the CAT1454 sequence contains three predicted
targets (25). [Region D that confers stress-mediated regu-
lation (25) is not included in these plasmids.] For psiCH-
CAT360, the forward primer 50-CATACTCGAGCACAG
CCCCGCCCCCCG-30 was used with the reverse
primer 50-TAGCGGCCGCGGAAGGCCTGGTTCC-30
for PCR ampliﬁcation of the CAT-1 30-UTR from a
cDNA clone obtained from Open Biosystems (ID
30340706) with subsequent cloning into Xho I and Not I
sites in psiCHECK-2. For psiCH-CAT1454, the reverse
primer 50-TAGCGGCCGCCATCAGCATGGGCCTTC
TGTCTCCT-30 was used. The primers were based on
those previously reported (25). All constructions were
conﬁrmed by DNA sequence analysis.
Cell culture
Human hepatoblastoma Huh7 and HepG2 cells were
grown in RPMI 1640 supplemented with L-glutamine,
25mM HEPES and 10% FBS. HEK-293T cells were
grown in DMEM supplemented with 4.5g/l glucose,
L-glutamine, sodium pyruvate and 10% FBS. All cells
were maintained in a humidiﬁed incubator at 378C and
5% CO2.
Silencing assays
For dual luciferase reporter assays of silencing, Huh7
cells were plated in 12-well plates and transfected using
Arrest-In (Open Biosystems, Huntsville, AL) according
to the manufacturer’s directions. The quantity of target
and eﬀector plasmids used in each transfection is indicated
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lysed and ﬁreﬂy and Renilla luciferase activities were
measured using the Dual-Glo Luciferase Assay System
(Promega, Madison, WI).
To assess silencing in the context of viral replication,
Huh7 cells were plated and transfected with pHBV/2
together with polycistronic silencing plasmids and the
reporter plasmid pGluc (New England Biolabs, Beverly,
MA, USA), as indicated in the legend of Figure 5. Two
days posttransfection, culture supernatants were harvested
and assayed for secreted HBV surface antigen (HBsAg)
using Genetic Systems HBsAg EIA 3.0 (Bio-Rad
Laboratories, Hercules, CA, USA) and for Gluc activity
using a Gaussia luciferase Assay Kit (New England
Biolabs).
Northern blot analysis of miRNA expression and
processing
HEK-293T cells were plated in six-well plates and
transfected with 250ng HBV-miRNA expression plasmid
(plus 1.75mg pUC19 DNA, added as ﬁller) by calcium
phosphate mediated transfection. Cells were collected
48h posttransfection and total RNA was isolated using
a mirVana RNA isolation kit (Ambion, Austin, TX,
USA). For each sample, 10mg of RNA was separated by
electrophoresis in a 12% polyacrylamide urea-TBE gel
and then electroblotted to BrightStar Plus nylon mem-
brane (Ambion). Blots were vacuum dried at 608C for
1h, prehybridized at 378C for 1h in ULTRAhyb-Oligo
hybridization buﬀer (Ambion) and then
32P-radiolabeled
oligonucleotide probe was added for overnight hybridiza-
tion at 378C. Blots were washed 3 times in 2  SSPE/0.1%
SDS at room temperature. Radiolabeled probes were
made by kinase end-labeling of 21nt oligonucleotides
complementary to the antisense (guide) strand of
mature HBV-miRNAs. Probe for U6 RNA was made
by random-primed radiolabeling of a 127bp DNA frag-
ment generated by PCR of human DNA. Hybridization
was detected using a Storm 820 (GE Healthcare)
phosphorimager. Blots were stripped by boiling brieﬂy
in 0.2  SSPE/0.1% SDS prior to hybridization with a
diﬀerent probe.
Immunoblot analysis
Cells were harvested 2 days posttransfection, washed in
PBS and lysed in 0.5  RIPA buﬀer with added complete
Protease Inhibitor Cocktail (Roche Applied Science,
Indianapolis, IN, USA). After electrophoresis in a 12%
polyacrylamide–SDS gel, proteins were transferred to
PVDF membrane and probed with a-actin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and a-EGFP
(Chemicon, Temecula, CA, USA) antibodies. Secondary
binding of horseradish peroxidase conjugated anti-
rabbit antibody (Sigma, St Louis, MO, USA) was detected
using Super Signal West Dura Extended reagent
(Pierce, Rockford, IL, USA) and imaged with a
FluorChem SP digital camera (Alpha Innotech, San
Leandro, CA, USA).
RESULTS
Silencing activity from multiplexed HBV-miRNAs
driven from pol III promoters
In previous work, we have described vectors that use RNA
pol II promoters to express up to four diﬀerent HBV-
miRNAs from a single polycistronic transcript (15). In
these vectors, the HBV-miRNAs are encoded in the con-
text of hsa-miR-30, including ﬂanking sequence of  40bp
50 and 30bp 30 of each stem-loop structure. The ﬂanking
sequence allows excision of the HBV-miRNAs from the
primary transcript as pre-miRNAs with further processing
to mature interfering RNAs via the cellular pathway used
for the generation of endogenous miRNAs. To date, RNA
pol III promoters have been used by many investigators to
express shorter and less complex RNAs, such as shRNAs
or individual miRNAs, where interfering RNAs can be
processed from a single stem-loop. However, a recent
report showing that miRNAs can be found encoded
downstream of some Alu repeats and can be processed
from the highly structured pol III Alu transcripts (26)
prompted us to test whether our multimerized HBV-
miRNAs could also be expressed from a pol III promoter.
As outlined in Figure 1, DNA encoding either two or four
individual HBV-miRNAs from our original pol II driven
constructs [(15), and see ‘Materials and Methods’ section]
was recloned downstream of a pol III promoter (either U6
or H1) in a pUC-based plasmid. Silencing activity of these
plasmids was tested in Huh7 cells, using a dual luciferase
assay based on the reporter vector, psiCHECK2. The re-
porter plasmid psiCH-HBV has the entire HBV genome
inserted into the 30-UTR of the Renilla luciferase expres-
sion cassette in psiCHECK2 such that transcripts contain
target regions for all of the HBV-miRNAs, as previously
described (15). Fireﬂy luciferase is expressed independent-
ly from the same plasmid and serves as a transfection ef-
ﬁciency control. Cells were transfected with a constant
amount of psiCH-HBV reporter plasmid together with
increasing amounts of each silencing plasmid. Results
shown in Figure 2a indicate that plasmids encoding
either two or four HBV-miRNAs are able to silence the
psiCH2-HBV reporter. Further, plasmids that use the U6
promoter are more potent than those that use the H1
promoter, as expected based on the relative strength of
these promoters (19,27). When directly compared with
our previously reported pol II driven polycistronic HBV-
miRNA expression plasmids, eﬃcacy is again related to
the predicted strength of the promoters, as shown in
Figure 2b. For instance, using 10ng of a bicistronic
plasmid, the LV (liver speciﬁc) and CMV pol II
promoter-driven eﬀector plasmids silence reporter expres-
sion to 70.2 and 44.1% of control levels (no added eﬀector
plasmid), while plasmids with the stronger H1 and U6 pol
III promoters direct silencing to 17.7 and 8.5% of
controls, respectively. Expression of miRNAs directed
against EGFP had no eﬀect on the HBV reporter.
Interestingly, plasmids that express four HBV-miRNAs
show slightly less silencing activity compared to plasmids
that express only two HBV-miRNAs from the same
pol III promoter (pUC-U6-2 versus pUC-U6-4 and
pUC-H1-2 versus pUC-H1-4 in Figure 2a). This eﬀect
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ference in size of the plasmids ( 7%) nor by saturation of
processing pathways, since the amount of silencing still
increases with plasmid dosage and promoter strength.
Instead, this may be a reﬂection of less than optimal trans-
cription, folding or processing of the longer quadraplexed
primary miRNA transcript, although potent silencing
activity is clearly retained for these plasmids.
Functional testing of individual HBV-miRNAs from
the polycistronic expression cassettes
The silencing activity of each miRNA encoded in the
polycistronic plasmids was tested using psiCH2 dual
luciferase reporter plasmids that contain insertions of
target sequence for each of the individual HBV-
miRNAs. Huh7 cells were transfected with a reporter plas-
mid carrying a single target region, together with a
polycistronic silencing plasmid (pUC-U6-2 or U6-4, or
pUC-H1-2 or H1-4). For comparison, monocistronic
plasmids with single HBV-miRNAs expressed from a U6
promoter were also cotransfected with reporter plasmids
carrying their cognate target. Results shown in Figure 3a
indicate that each of the HBV-miRNAs is roughly as
active in the context of polycistronic expression as it is
when expressed from a monocistronic silencing plasmid.
We again see somewhat less activity from plasmids that
encode four miRNAs as compared to those with two, and
stronger activity from the U6 plasmids than from the H1
plasmids. These results support the conclusion that the
overall silencing potency of the polycistronic plasmids
observed in Figure 2 reﬂects the combined eﬀects of
each component miRNA, and not an activity dominated
by a single miRNA.
The silencing activity of the 2910 HBV-miRNA was
weak at the low dose tested (Figure 3a) whether it was
expressed alone from a monocistronic plasmid or as the
most distal stem-loop in a polycistronic plasmid.
Nevertheless, this result raised the question as to whether
pol III promoters are capable of expressing as many as
four miRNAs or lose activity over the span of several
stem-loop structures. To address this, we constructed
plasmids where the order of the four HBV-miRNAs was
rearranged, placing 2910 in the ﬁrst position, followed by
2791, 1737 and 1907 (Figure 1b). Figure 3b shows results
of a transfection experiment comparing the activity of
individual HBV-miRNAs against their cognate target
sequence when they are placed in a diﬀerent order in
the polycistronic silencing plasmid (pUC-U6-4 versus
pUC-U6-4R). Here, it is evident that moving 2910 and
2791 miRNAs to the ﬁrst and second positions dramatic-
ally improves their potency. At the same time, 1737 and
1907 miRNAs did not lose any potency when encoded in
more distal positions. While a full explanation of this
eﬀect needs further investigation, we can conclude that
pol III is able to transcribe at least four miRNAs. We
note that there are no stretches of greater than three T
residues that could lead to transcriptional termination in
the HBV-miRNA coding region of any of our plasmids.
It seems likely that, depending on the sequence of each of
the component miRNAs, changes in their position can
Figure 1. Organization of cassettes for RNA pol III driven expression of miRNAs. (a) General structure of an expression cassette with a pol III
promoter and restriction sites for insertion of DNA encoding a pre-miRNA. Facing block arrows (light gray) represent DNA encoding the stem
portion and open bars show the ﬂanking and loop sequences for each pre-miRNA. The shaded bar (dark gray) shows the pol III promoter and the
(dT)6 pol III termination signal is indicated. The predicted structure of the pre-miRNA transcript is shown at the right, including sequence from the
hsa-miR30 ﬂanking regions that form a partially base paired structure at the base of the stem-loop necessary for recognition by the Drosha/DGCR8
microprocessor complex (40). Hash marks next to the stem-loop show predicted cleavage positions for processing to mature miRNA. (b) Structure of
DNA encoding the bicistronic and polycistronic HBV-miRNAs and their RNA transcripts. DNA encoding the 1737B/1907A pre-HBV-miRNAs was
inserted downstream of a pol III H1 or U6 promoter in a pUC-based plasmid to produce the bicistronic H1-2 and U6-2 silencing plasmids.
Sequential insertion of XbaI/SpeI fragments encoding individual 2791B or 2910A pre-HBV-miRNAs produced the polycistronic cassettes H1-4
and U6-4. The position of insertion of individual HBV pre-miRNAs was changed to generate the rearranged cassettes, H1-4R and U6-4R. HBV-
miRNAs are numbered according to their target site in the HBV genome. The expected structure of transcripts from each cassette is shown at the
right, with individual HBV-miRNA stem-loops numbered (1–4) to highlight their order in the primary transcript.
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transcript, as noted earlier.
Detection of mature miRNA derived from each of the
multiplexed HBV-miRNAs
A further test of the expression of all four HBV-miRNAs
was performed by northern blot analysis to detect mature
miRNAs produced from the polycistronic plasmids.
HEK-293T cells were transfected with U6 driven
monocistronic plasmids expressing each of the individual
HBV-miRNAs or with the pUC-U6-4, pUC-H1-4 or
pUC-U6-4R polycistronic plasmids. RNA isolated from
the transfected cells was analyzed by sequential hybrid-
ization of blots using radiolabeled probes to detect each
of the HBV-miRNAs, or U6 RNA as a loading control.
Figure 4 shows that similar mature miRNAs can be
detected for each of the HBV-miRNAs when they are
expressed from mono- or polycistronic plasmids.
Silencing of HBV RNAs in the context of viral replication
In order to conﬁrm that the plasmids can silence HBV
transcripts in the context of viral replication, the pUC-
U6-4 and pUC-U6-4R plasmids were tested by
cotransfection with a plasmid that produces infectious
HBV. Huh7 cells were cotransfected with pHBV/2,
increasing amounts of pUC-U6-4 or pUC-U6-4R, and
pGluc. Two days posttransfection, cell supernatants
were assayed for secretion of HBsAg as an indicator of
viral replication and Gaussia luciferase as a transfection
eﬃciency control. Normalized HBsAg levels, as shown in
Figure 5, indicate that the polycistronic plasmids are
potent inhibitors of viral replication. The re-arranged
order of HBV-miRNAs found in pUC-U6-4R leads to
stronger overall silencing as expected from the higher
silencing activity of the individual miRNAs, as shown in
Figure 3b.
The endogenous miRNA pathway is not saturated by
pol III expression of polycistronic HBV-miRNAs
Concerns have been raised about potential toxic eﬀects
from high levels of exogenous expression of interfering
RNAs due to competition for components of the endogen-
ous miRNA processing pathway (19–22). As an initial test
of whether expression of the multiplexed HBV-miRNAs
from a pol III promoter can saturate miRNA pathways,
we looked for changes in the silencing activity of endogen-
ously expressed miR-122 in transfected Huh7 cells.
A psiCHECK-2 reporter with a single, perfectly matched
miR-122 target sequence inserted into the 30-UTR of
the Renilla luciferase gene was used in these assays. In
order to demonstrate miR-122-directed silencing of this
reporter, we used it to transfect both Huh7 cells, which
have high levels of miR-122, and HepG2 cells, which do
not express miR-122. Results shown in Figure 6a conﬁrm
that the psiCH2-122 reporter is strongly suppressed
in Huh7 cells, but not in HepG2 cells. The psiCH2-122
reporter plasmid was then transfected into Huh7 cells
together with increasing amounts of pUC-U6-2, pUC-
U6-4 or pUC-H1-4. Cells were also transfected with
the psiCH2 plasmid, with no target, as a control for
luciferase expression. When cells were assayed 2 days
posttransfection, as shown in Figure 6b, there was no sig-
niﬁcant decrease in the miR-122 directed silencing of the
reporter plasmid in the presence of any of the eﬀector
plasmids, even at doses ﬁve times higher than required
for potent silencing of HBV targets (Figure 2).
We also tested whether expression of the HBV-miRNAs
can cause a reduction in the activity of endogenous miR-
122 against incompletely matched, validated targets found
in the 30-UTR of human CAT-1 mRNA (25,28). The dual
luciferase reporter constructs psiCH-CAT360 and psiCH-
CAT1454 contain sequence derived from the ﬁrst 360nt
or 1454nt of the CAT-1 30-UTR, and correspond,
respectively, to the RL-catC and RL-catB reporter
plasmids of Bhattacharyya et al. (25). The CAT360
30-UTR does not contain predicted miR-122 target sites
and the CAT1454 30-UTR contains three predicted
targets (25). Despite the absence of miR-122 in HepG2
cells, normalized Renilla luciferase activity (Rluc/Fluc)
Figure 2. Silencing activity of polycistronic miRNA constructs.
(a) Huh7 cells were transfected with 250ng of a dual luciferase reporter
plasmid, psiCH-HBV, which contains sequence targeted by all four of
the HBV-miRNAs, together with no silencing plasmid or increasing
amounts of plasmids carrying the U6-2, U6-4, H1-2 or H1-4 HBV-
miRNA expression cassettes, as indicated. Cotransfection with the
reporter plasmid and 10ng of a U6-miEGFP silencing plasmid
(miEGFP) served as a negative control. Silencing activity was measured
as the ratio of Renilla to ﬁreﬂy luciferase activity in cell lysates 2 days
posttransfection, and results are reported as percent of control with no
added silencing plasmid. Data represent the average ( SD) of triplicate
assays of two separate transfections. (b) Huh7 cells were transfected
with plasmids expressing two HBV-miRNAs from a pol II promoter
[pCMV-30s-1737B/1907A and pLV-30s-1737B/1907A, see (15)] or the
corresponding pol III driven cassettes (pUC-H1-2 and pUC-U6-2) and
analyzed as in (a).
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transfected with 5ng of monocistronic or polycistronic HBV-miRNA expression plasmids, together with 250ng of a dual luciferase reporter plasmid
carrying target for an individual HBV-miRNA, as indicated. (b) Huh7 cells were again cotransfected with monocistronic or polycistronic silencing
plasmids together with a reporter plasmid carrying individual target sequences, as indicated. Here, the order of insertion of the HBV-miRNAs has
been rearranged in the U6-4R construct relative to U6-4 (Figure 1). Data represent the average ( SD) of triplicate assays of two separate
transfections.
Figure 4. Fully processed miRNA can be detected for each component of the polycistronic HBV-miRNA transcript. RNA was isolated from HEK-
293T cells either not transfected or transfected with monocistronic or polycistronic vectors expressing HBV-miRNAs, as indicated above each lane.
Two diﬀerent blots (right and left panels) were probed sequentially for miRNAs or U6 RNA, as indicated to the right of each image.
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psiCH-CAT1454, relative to psiCH-CAT360 (Figure 6c).
Similar results were observed by Bhattacharyya et al. (25),
using their reporter plasmids. However, a stronger
suppression of Renilla luciferase is observed in Huh7
cells, where Rluc/Fluc activity from psiCH-CAT1454 is
reduced by 74% relative to that from psiCH-CAT360,
reﬂecting silencing by miR-122 (25). With the addition
of increasing amounts of the HBV-miRNA bicistronic
expression vector pUC-U6-2, there was little recovery of
Rluc expression in Huh7 cells. Although a slight and
apparently dose-dependent increase in the Rluc/Fluc
ratio was observed with higher doses of pUC-U6-2, the
diﬀerence from control values did not reach statistical
signiﬁcance, even at levels that provided strong silencing
of HBV targets (Figure 2).
In another set of experiments, we tested whether HBV-
miRNAs expressed from our plasmids can compete for
processing of a co-expressed miRNA. Here, HEK-293T
cells were transfected with a plasmid that expresses a
destabilized form of EGFP, pCMV-dsEGFP and the
silencing plasmid, pUC-U6-30/EGFP, in the absence or
presence of increasing amounts of potential competitor
plasmids, pUC-U6-2 or pUC-U6-4. Two days posttrans-
fection, cells were lysed and assayed by immunoblot ana-
lysis for the expression EGFP. Results in Figure 6d show
that EGFP is eﬀectively silenced by pUC-U6-30/EGFP,
and there is little or no suppression of that activity
even in the presence of high doses of HBV-miRNA
expression plasmids. Therefore, we see minimal evidence
Figure 6. The polycistronic HBV-miRNAs show minimal competition for activity of endogenous miR-122 in Huh7 cells or exogenously expressed
miEGFP in HEK-293T cells. (a) Huh7 cells or HepG2 cells were transfected with psiCHECK-2 (psiCH2) or with psiCH2-122 where perfectly
matched target sequence for miR-122 has been inserted downstream of the Renilla luciferase coding region. Results represent the average ( SD) of
two separate transfections assayed in duplicate. (b) Huh7 cells were transfected with psiCH2-122 together with no silencing plasmid, or with
increasing amounts of pUC-U6-2, pUC-U6-4 or pUC-H1-4 as indicated. As a control for reporter expression, cells were transfected with the
psiCH2 plasmid, in the absence of silencing plasmid. Results show the average ( SD) of three separate transfections assayed in triplicate. For
both (a) and (b), cells were lysed 2 days posttransfection and luciferase activity was assayed as in Figure 2. (c) HepG2 or Huh7 cells were transfected
with psiCH-CAT360 or psiCH-CAT1454 together with the indicated amount of pUC-U6-2. Cells were lysed 3 days posttransfection and assayed as
in Figure 2. Results show the average ( SD) of three separate transfections for HepG2 cells, and six transfections for Huh7 cells. (d) 293T cells were
transfected with pCMV-dsEGFP in the absence of silencing plasmid, or with a constant amount of pUC-U6-miEGFP silencing plasmid plus
increasing amounts of pUC-U6-2 or pUC-U6-4, as indicated. Immunoblot analysis of protein extracts prepared 2 days posttransfection was carried
out using a-EGFP and a-actin antibodies. Duplicate lanes show results from two separate transfections for each set of experimental conditions.
Numbers below each lane indicate the percent EGFP present relative to control (average of no miEGFP values) after normalization to actin.
Figure 5. Antiviral activity of the polycistronic HBV-miRNA plasmids.
Huh7 cells were transfected with 100ng pHBV/2, an infectious molecular
clone of HBV, together with no silencing plasmid or increasing amounts
of pUC-U6-4 or pUC-U6-4R, as indicated. pGLuc (50ng) was included
as a transfection eﬃciency control. Two days posttransfection, culture
supernatants were assayed for HBV S-antigen (HBsAg) and results
were normalized to secreted GLuc activity. Results are reported as per-
cent of HBsAg secretion in the absence of silencing plasmid and represent
the average ( SD) of two separate transfections assayed in triplicate.
PAGE 7 OF 10 Nucleic Acids Research, 2009,Vol.37, No. 19 e127of competition for the activity of an endogenous, largely
pre-existing miRNA (miR-122) or for the processing of a
co-expressed miRNA (miEGFP) in the presence of the pol
III driven polycistronic HBV-miRNAs.
DISCUSSION
In the work presented here, we have shown that it is pos-
sible to drive polycistronic expression of miRNAs from a
pol III promoter. This is an important addition to the
current selection of designs available for the expression
of multiplexed silencing RNAs that has the advantage
of producing high levels of multiple miRNAs from a com-
pact cassette. The miRNAs are processed from a single
precursor and are expressed at similar levels so that overall
silencing is not dominated by one member of the set. The
expression unit is small and nonrepetitive and can be
incorporated into a variety of plasmid or viral vectors.
Plasmids designed to express as many as four HBV-
miRNAs show strong silencing of viral targets in reporter
systems and in a cell culture model of viral replication.
Most endogenous miRNAs are transcribed from pol II
promoters (29,30) and several groups, including our own,
have used these promoters to construct vectors for
multiplexed expression of silencing RNAs designed to
resemble miRNAs (14–17,31–33). Pol II promoters allow
a degree of targeting by cell type-speciﬁc expression or
regulation, and therefore can be a good choice for use in
vectors that will be delivered broadly to a range of tissues
in an organism. However, there can also be advantages to
the stronger expression possible from pol III promoters,
particularly when using low or single-copy vectors. Until
now, the use of pol III promoters has been limited by their
ability to express only a single shRNA, making it neces-
sary to introduce a separate promoter to drive each
shRNA in vectors designed for multiplexed expression
(8–12). The ﬁnding that naturally occurring miRNAs
can be encoded directly downstream of Alu repeat
sequences and processed from these highly structured
pol III transcripts (26) suggested that it would be possible
to express several functional interfering RNAs from a
single pol III promoter if they were formatted as
miRNAs. Although the Alu transcripts are driven by
type 2 pol III promoters, with elements internal to the
transcript, we chose to use U6, H1 and 7SK (not shown)
type 3 promoters that are located upstream of the tran-
scription start site and are, therefore, more convenient to
use in gene constructions. We show that pol III is capable
of transcribing through at least four structured hairpin
regions and that functional miRNAs can be processed
from these transcripts. We also show that the order in
which particular hairpins are encoded in the polycistronic
transcript can aﬀect their silencing potency. Whether this
is due to sequence elements or structure that might cause
premature termination of transcription or to sequence-
speciﬁc folding or processing eﬀects needs to be studied
further.
While pol III promoters are naturally ubiquitously and
constitutively expressed, they can be modiﬁed and made
inducible (34–36). Since their regulation would require
the expression of nonendogenous transactivator or repres-
sor proteins, this could be diﬃcult to implement
therapeutically. Nevertheless, the use of inducible pol III
promoters could be a useful modiﬁcation to our vector in
research applications.
Strong silencing activity, together with multiplexed
targeting, has been shown to be important in maximizing
eﬃcacy and reducing viral escape both by mathematical
modeling (18) and by experimentation (12,13,19). At the
same time, however, high levels of shRNA produced from
pol III promoters have been associated with cellular
toxicity. For instance, AAV vectors directing the expres-
sion of certain shRNAs in the liver were lethal to mice
when delivered at high dose (20). Similarly, neurotoxicity
observed in the brains of mice injected with shRNA-AAV
vectors correlated with high levels of shRNA production
(21). Additional studies have indicated that expression of
shRNAs from a strong U6 promoter in lentiviral vectors
can lead to potent silencing of targets in transduced per-
ipheral blood lymphocytes, but also causes cytotoxicity,
while lower levels of expression from the H1 promoter
are tolerated (19). Although not fully understood, the tox-
icity caused by high levels of shRNA expression has been
attributed to saturation or competition for components of
the endogenous miRNA processing pathway (20,22) or to
oﬀ-target eﬀects caused by the accumulation of excessive
amounts of antisense RNAs (21).
Importantly, evidence is emerging that silencing RNAs
that are produced in the format of endogenous miRNAs,
and presumably undergo nuclear processing by the
Drosha/DGCR8 complex, do not display the same
toxicities as shRNAs even though they can have compar-
able or better silencing potency (21,22). In hepatocytes
transfected with relatively large amounts of our pol III
driven polycistronic HBV-miRNA expression plasmids,
we see minimal reductions in the silencing activity of
endogenous miR-122 against either a perfectly matched
target sequence or against imperfectly matched, conﬁrmed
targets from the 30-UTR of human CAT-1 mRNA. We
also see little evidence of competition for miRNA
processing when these plasmids are cotransfected into
HEK-293T cells with a pol III driven miEGFP expression
plasmid. It is important to note, however, that the results
of competition as evaluated in transient transfection
assays can be inﬂuenced by the ratio of target to
interfering RNA, the ratio of interfering RNA to com-
petitor, the sequence of the interfering RNA and available
processing pathway components in any given cell type
(37–39). Undoubtedly there are levels of expression at
which these pathways become saturable. While more strin-
gent testing in animal models will be necessary to charac-
terize potential toxicities, our initial results suggest that
potent silencing can be achieved from small amounts of
vector without triggering the strong competitive eﬀects
associated with shRNA expression.
In summary, we describe the use of RNA pol III
promoters for polycistronic expression of interfering
RNAs. We ﬁnd that formatting them as miRNAs allows
the processing and expression of at least four interfering
RNAs from a single pol III transcript, providing potent
silencing without the evidence of saturation of endogenous
e127 Nucleic Acids Research, 2009, Vol. 37,No. 19 PAGE8 OF10miRNA pathways. This compact design will add to
the versatility of silencing vectors in both research and
therapeutic applications.
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